https://www.selleckchem.com/products/ei1.html 2). Predictors of LDA were being biologic-naïve [aOR 2.53 (1.31–4.88); 95% CI] and RF negativity [aOR 2.14 (1.12–4.07); 95% CI]. At 1 year, the overall tofacitinib retention rate was 63.9% with no relevant predicting factor. Response and retention rates of tofacitinib were similar in patients with and without concomitant csDMARDs. Treatment failure was the most common cause of discontinuation. The most common infectious and laboratory adverse events were herpes zoster infection (3.9 per 100 patient-years) and elevation in ALT (x3UNL 9.7 per 100 patient-years), respectively. Tofacitinib is effective as monotherapy or in combination with csDMARDs. It is a well-tolerated treatment option in Turkish RA patients. Tofacitinib is effective as monotherapy or in combination with csDMARDs. It is a well-tolerated treatment option in Turkish RA patients. To evaluate the potential protective effects of Ankaferd blood stopper(ABS) in experimental Obstructive jaundice (OJ) model. The study included 26 female rats which were divided into 3 groups. The sham group, consisting 10 rats, (Group 1) only received solely laparotomy. In the control group, consisting 8 rats, (Group 2), ligation was applied to the biliary tract and no treatment was implemented. In the treatment group, consisting 8 rats, (Group 3), following ligation of biliary tract, 0.5 ml/day ABS was given for 10 days. Liver tissue and blood samples were taken for histopathological and biochemical examination. Compared to group 2, group 3 had higher aspartate aminotransferase (AST), total oxidant status (TOS) malondialdehyde (MDA), fluorescent oxidant products (FOP) and lower expression of albumine and total antioxidant status (TAS) (p<0.05). In histopathological analysis, the mean scores of all histopathological parameters (fibrosis, portal inflammation, confluent necrosis, interphase activity, bile duct proliferation) have statistical significance between group 2 and group 3 (